Dr. Michael Sherman serves as chief medical officer and senior vice president for health services for Harvard Pilgrim Health Care, a not-for-profit health plan that has been recognized by NCQA as one of the top health plans in the nation for over a decade. A pioneer in developing outcomes-based payment agreements with pharmaceutical companies that go beyond the historical “pay for pill” approach and tie reimbursement to patient outcomes, he recently signed the first value-based agreement for a gene therapy used to treat a form of blindness. Dr. Sherman serves as chair of the Board of Managers of the Harvard Pilgrim Health Care Institute, which encompasses the Department of Population Medicine at Harvard Medical School and is the only appointing medical school department in the US based in a health plan and on the Advisory Board of the Institute for Clinical and Economic Review (ICER).Dr. Sherman often speaks at national and regional conferences, most frequently on the subject of outcomes-based pharmaceutical agreements. He currently serves on the board of advisors for the Harvard Business School Healthcare Initiative and board of overseers for Boston’s internationally renowned Museum of Science.